Frequencies of two functionally significant SNPs and their haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in six ethnic groups of Pakistani population

Iranian Journal of Basic Medical Sciences

Volumn 17, Issue 6, 2014, Pages 441-447

  Rajput, Tausif Ahmed ^a   Naveed, Abdul Khaliq ^a   Khan, Shakir ^a   Farooqi, Zia Ur Rehman ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Haplotype; OATP1B1; Single nucleotide polymorphism; SLCO1B1

Indexed keywords

GENOMIC DNA;

ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ETHNIC GROUP; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; PAKISTAN; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE; TETRA AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION;

EID: 84903382540     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Giacomini KM, Sugiyama Y. Goodman and Gillman's the pharmacological basis of therapeutics. Brunton LL, Lazo JS, Parker KL. New York: McGraw-Hill; 2006.
2. Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008; 9:597-624.
3. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8:787-802.
4. Seithel A, Glaeser H, Fromm MF, Konig J. The functional consequences of genetic variations in transporter genes encoding human organic aniontransporting polypeptide family members. Expert Opin Drug Metab Toxicol 2008; 4:51-64.
5. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 9:19-33.
6. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004; 19:453-455.
7. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013; 19:1458-1466.
8. Anne TN, Mikko N, Oliver B, Stefan W, Ulrich MZ, Bruno S, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 2013; 5:1.
9. Zhu J, Song M, Tan HY, Huang LH, Huang ZJ, Liu C, et al. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. Pak J Pharm Sci 2013; 26:577-584.
10. Zhou Q, Ruan ZR, Jiang B, Yuan H, Zeng S. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Die Pharmazie 2013; 68:124-128.
11. Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Die Pharmazie 2013; 68:187-194.
12. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug dispos 2013; 34:45-78.
13. Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther 2013; 93:275-282.
14. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14:429-440.
15. Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 and SLCO1B1 Polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of egyptian patients with hypercholesterolemia. Mol Diagn Ther 2013; 17:299-309.
16. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, et al. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics 2013; 23:355-364.
17. Scarpini F, Cappellone R, Auteri A, Puccetti L. Role of genetic factors in statins side-effects. Cardiovasc Hematol Dis Drug Targets 2012; 12:35-43.
18. Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP. New therapies to reduce low-density lipoprotein cholesterol. Curr Opin Cardiol 2013; 28:452-457.
19. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 2013; 5:1.
20. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa Populations. PloS One 2013; 8:e67946.
21. Qaigen. QIAamp DNA Mini and Blood Mini Handbook. 2nd ed. Qaigen, Helden, Germany: 2007.
22. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29:E88-98.
23. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 2010; 10:564-567.
24. Slatkin M. Linkage disequilibrium in growing and stable populations. Genetics 1994; 137:331-336.
25. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Konig S, Ziesenitz V, et al. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method. Eur J Clin Pharm 2011; 67:1139-1145.
26. Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 2011; 12:136.
27. Sortica Vde A, Ojopi EB, Genro JP, Callegari-Jacques S, Ribeiro-Dos-Santos A, de Moraes MO, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharm Toxicol 2012; 110:460-468.
28. Jada SR, Xiaochen S, Yan LY, Xiaoqiang X, Lal S, Zhou SF, et al. Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharm 2007; 63:555-563.
29. Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharm 2010; 50:929-940.
30. Boivin AA, Cardinal H, Barama A, Pichette V, Hebert MJ, Roger M. Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians. Drug Metab Pharmacokinet 2010; 25:508-515.
31. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006; 62:409-415.
32. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol 2008; 64:257-266.
33. Endo S, Fukahori A, Tokuhiro S, Shinagawa A, Walker J, Yoshihara K, et al. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure. J Hum Genet 2012; 57:531-544.